Zinc Finger Repressors mediate widespread PRNP lowering in the nonhuman primate brain and profoundly extend survival in prion disease mice
Chou, S.-W.; Mortberg, M. A.; Marlen, K.; Ojala, D. S.; Parman, T.; Howard, M.; DeSouza-Lenz, K.; Lian, Y.; Mehrabian, M.; Tiffany, M.; Ledeboer, A.; Dunn, P.; Hu, J.; Guzman, K.; Kamath, N.; Cass, M.; Graffam, S.; Xu, L. M. H.; Laversenne, V.; Corridon, T. L.; Falcon, A.; Lew, G.; Sajuthi, S.; Zhang, L.; Cisbani, G.; Peters, F.; Fieblinger, T.; Melis, C.; Barenberg, J.; Hnatiuk, M.; Yu, Q.; Chung, D.; Jalan, M.; Hinkley, S.; Lu, Y.; Meyer, K.; Coffey, A.; Pooler, A. M.; Vallabh, S. M.; Minikel, E. V.; Zeitler, B.
Show abstract
Prion disease is a rapidly progressing and invariably fatal neurodegenerative disorder with no approved treatment. The disease is caused by the self-templated misfolding of the prion protein (PrP) into toxic species, ultimately leading to neurodegeneration and death. We evaluated a novel epigenetic regulation approach using Zinc Finger Repressors (ZFRs) to ablate PrP expression at the transcriptional level. When delivered using adeno-associated virus (AAV), ZFRs potently and specifically reduced prion mRNA expression by >95% in vitro and to near undetectable levels within single neurons in vivo. In wildtype mice, ZFRs stably lowered neuronal PrP expression throughout the central nervous system for at least 17 months. In mice inoculated with misfolded PrP, AAV-ZFRs given at either early or late disease stages profoundly extended lifespan, significantly reduced PrP in the brain, and improved an array of molecular, histological, biomarker, and behavioral readouts. Finally, we delivered a ZFR targeting the human prion gene (PRNP) to cynomolgus monkeys using a novel blood-brain-barrier penetrant AAV capsid. Extensive bulk and single-cell assessments revealed widespread ZFR expression and PRNP repression in all 35 brain regions assessed, providing the first demonstration of epigenetic regulation across the nonhuman primate neuraxis following a single intravenous (IV) dose. These results highlight the potential of a one-time IV administered ZFR treatment for prion disease and other neurological disorders.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- CRISPR/Cas9-Mediated Excision of ALS/FTD-Causing Hexanucleotide Repeat Expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro 96%
- Mitigating a TDP-43 proteinopathy by targeting ataxin-2 using RNA-targeting CRISPR effector proteins 95%
- Suppression of Huntington's Disease Somatic Instability by Transcriptional Repression and Direct CAG Repeat Binding 95%
Similar papers in this journal
Similar papers in this journal
- RNAi-mediated silencing of SOD1 profoundly extends survival and functional outcomes in ALS mice 95%
- Therapeutic suppression of Tubb4a rescues H-ABC leukodystrophy 94%
- Administration of barcoded AAV capsid library to the putamen of non-human primates identifies variants with efficient retrograde transport 94%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.